All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000537-11 | An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITP | 2006-03-28 | due-trials |
| Reported results | 2004-001186-17 | Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks | 2008-05-16 | due-trials |
| Reported results | 2004-004868-69 | Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease | 2006-01-31 | due-trials |
| Reported results | 2005-000382-19 | Efficacy and tolerance of BERIPLEX® P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation | 2007-02-28 | due-trials |
| Reported results | 2005-000651-14 | A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine, CSL Limited in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for t... | 2005-06-25 | due-trials |
| Trial is outside EEC, and reported results | 2005-003139-38 | Open-label extension study of CE1145 (Human pasteurized C1 esterase inhibitor concentrate) in subjects with congenital C1-INH deficiency and acute HAE attacks | bad-data | |
| Reported results | 2005-003331-44 | A Randomized, Observer-Blind, Single-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Enzira 2005/2006 compared to Mutagrip 2005/2006 in Healthy 'Adults@ aged >18 to <60 years a... | 2005-11-17 | due-trials |
| Reported results | 2005-003459-12 | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly i.v... | 2013-03-14 | due-trials |
| Reported results | 2006-002068-25 | A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for the 2006/2007 Northern He... | 2006-06-23 | due-trials |
| Reported results Terminated | 2006-004354-24 | A Phase IV, Randomised, Observer-Blind,Comparator-Controlled, Single-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Influenza Vaccine (Enzira) (2006/2007) in Healthy Older... | 2006-12-08 | due-trials |
| Reported results | 2006-006023-39 | Pharmacokinetics of Haemocomplettan P in subjects with congenital fibrinogen deficiency | 2008-05-15 | due-trials |
| Reported results | 2006-006522-25 | A Multicenter study on the efficacy and safety of Vivaglobin in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID) | 2008-10-31 | due-trials |
| Reported results | 2006-006745-13 | A Multicenter Study of the Efficacy, Tolerability, Safety and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency | 2009-08-31 | due-trials |
| Reported results | 2007-000272-16 | A Phase II, Double Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 years) and Older Ad... | 2008-06-19 | due-trials |
| Reported results | 2007-000710-37 | A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN) | 2009-01-05 | due-trials |
| Reported results | 2007-001465-14 | A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira Vaccine in Healthy Adults aged ≥ 18 to < 60 years and in Healthy Older Adults aged ≥ 60 years for the 2007/2008 No... | 2007-06-22 | due-trials |
| Reported results Terminated | 2007-004088-22 | Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency | 2014-02-28 | due-trials |
| Reported results | 2007-004612-31 | Efficacy and safety of Haemocomplettan® P in patients experiencing acute bleeding while undergoing aortic replacement surgery | 2010-04-21 | due-trials |
| Reported results | 2007-007129-38 | An open, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira® administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due ... | 2015-09-18 | due-trials |
| Completed, but no date, and reported results | 2007-007861-19 | An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin deriva... | bad-data | |
| Reported results | 2007-007862-39 | A open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivat... | 2013-02-22 | due-trials |
| Reported results | 2008-000830-30 | A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency (IgPro20 EU Extension Study) | 2011-12-21 | due-trials |
| Reported results | 2008-001104-23 | A Phase II, multicentre, double-blinded, randomised, cross-over study to evaluate efficacy, safety and pharmacokinetics of Biostate® in subjects with Haemophilia A. | 2010-10-15 | due-trials |
| Reported results | 2008-001422-14 | A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008/20... | 2008-11-14 | due-trials |
| Completed, but no date, and reported results | 2008-004922-18 | An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects with Von Willebrand Disease. | bad-data | |
| Reported results | 2008-005324-93 | A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008/20... | 2008-10-19 | due-trials |
| Reported results | 2009-010387-41 | A 12-week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects with Congential Factor XIII Deficiency Estudio de 12 semanas, multicéntrico, de fa... | 2010-02-24 | due-trials |
| Reported results | 2009-010722-19 | A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects with Congenital Factor XIII Deficiency Estudio prospectivo, multicéntrico, con etiqu... | 2011-06-16 | due-trials |
| Reported results | 2009-011450-18 | A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged ≥ 18 to < ... | 2009-05-28 | due-trials |
| Reported results | 2009-015112-18 | A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects with Haemophilia A. | 2014-07-01 | due-trials |
| Reported results | 2009-017301-11 | An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies CSLC... | 2014-03-28 | due-trials |
| Reported results | 2009-017672-24 | A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) | 2011-11-29 | due-trials |
| Reported results | 2009-017753-34 | A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease. | 2013-08-27 | due-trials |
| Exempt, with results | 2010-018477-38 | An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B. | 2011-07-22 | not-yet-due |
| Reported results | 2010-019532-12 | A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 y... | 2011-05-27 | due-trials |
| Reported results | 2010-020113-85 | A Multi-center, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune Tol... | 2014-03-07 | due-trials |
| Reported results | 2010-024242-30 | Prospective open-label uncontrolled multi-center post-marketing study to assess inhibitory antibody formation in subjects with congenital C1-INH deficiency and acute hereditary angioedema (HAE) attack... | 2014-11-14 | due-trials |
| Reported results | 2011-000263-27 | An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated with ... | 2014-09-17 | due-trials |
| Reported results | 2011-002393-23 | A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII ... | 2015-01-30 | due-trials |
| Reported results | 2011-002415-28 | A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B Studio di fase II/III, multi... | 2014-07-21 | due-trials |
| Reported results | 2011-002685-20 | REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study... | 2014-09-14 | due-trials |
| Reported results | 2011-003448-28 | Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglob... | 2016-09-20 | due-trials |
| Reported results | 2011-006032-23 | A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children w... | 2014-10-05 | due-trials |
| Reported results | 2012-001101-24 | A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 y... | 2012-06-01 | due-trials |
| Reported results | 2012-001309-26 | A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors. | 2018-04-05 | due-trials |
| Reported results | 2012-001336-65 | A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population with Severe Hemophilia A | 2015-08-24 | due-trials |
| Reported results | 2012-005489-37 | A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B | 2021-06-02 | due-trials |
| Reported results | 2013-000916-10 | A double-blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophy... | 2015-10-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003262-13 | A Phase 3 Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A | 2021-01-19 | bad-data |
| Reported results | 2013-003305-25 | An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease | 2018-02-15 | due-trials |
| Reported results | 2013-003458-26 | A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infa... | 2017-03-21 | due-trials |
| Reported results | 2013-004157-24 | Multicenter, open-label extension study to investigate the long-term safety and efficacy of IgPro20 in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in subjects com... | 2017-07-10 | due-trials |
| Reported results | 2014-001054-42 | An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of her... | 2017-09-21 | due-trials |
| Trial is outside EEC, and reported results | 2014-003409-13 | A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects with Primary Immunodeficiency | bad-data | |
| Trial is outside EEC, and reported results | 2014-003605-15 | A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID) | bad-data | |
| Trial is outside EEC, and reported results | 2014-003607-30 | A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodefic... | bad-data | |
| Trial is outside EEC, and reported results | 2014-003608-61 | A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency | bad-data | |
| Trial is outside EEC, and reported results | 2014-003609-14 | A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency | bad-data | |
| Trial is outside EEC, and reported results | 2014-003764-20 | A Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency | bad-data | |
| Trial is outside EEC, and reported results | 2014-003768-19 | A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-V... | bad-data | |
| Trial is outside EEC, and reported results | 2014-003772-23 | A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004131-40 | A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a paediatric population aged greater than or equal to 6 months to less th... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005183-15 | A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-005401-20 | An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD) | bad-data | |
| Trial is outside EEC, and reported results | 2015-000176-10 | A Phase II, Multicenter, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL’s 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatr... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000177-12 | An Observer-Blind, Randomized, Comparator-Controlled, Single-Centre Study to Evaluate the Tolerability, Safety, and Immunogenicity of Inactivated Influenza Vaccine, CSL Limited in a Healthy Pediatrics... | bad-data | |
| Reported results | 2015-003017-26 | A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Modera... | 2017-06-28 | due-trials |
| Trial is outside EEC, and reported results | 2015-004820-69 | An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age). | bad-data | |
| Trial is outside EEC, and reported results | 2015-004977-34 | Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra®) on weekly and biweekly schedules | bad-data | |
| Trial is outside EEC, and reported results | 2016-001631-12 | Prospective open-label single-arm study of the pharmacokinetics and safety of intravenous IgPro10 in Japanese subjects with primary immunodeficiency | bad-data | |
| Reported results Terminated | 2016-002510-50 | A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A | 2020-03-31 | due-trials |
| Trial is outside EEC, and reported results | 2016-003798-16 | Comparison of 2 Infusion Devices with Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra®: Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | bad-data | |
| Trial is outside EEC, and reported results | 2016-003799-33 | An open-label multicenter study to evaluate the safety and tolerability of higher infusion parameters of immune globulin subcutaneous (human), 20% liquid (Hizentra®) in subjects with primary immunodef... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-000348-17 | A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Ref... | 2020-12-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000996-98 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome | 2023-11-17 | bad-data |
| Ongoing | 2017-004305-40 | Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AA... | not-yet-due | |
| Other | 2018-000329-29 | A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients rec... | not-yet-due | |
| Reported results | 2018-000605-24 | A multicenter, randomized, placebo-controlled, parallel-arm study to investigate the efficacy, pharmacokinetics, and safety of CSL312 in subjects with hereditary angioedema | 2021-10-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-003149-41 | A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobuli... | 2022-05-17 | bad-data |
| Other | 2018-003171-35 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) Étude destinée à évaluer l'efficacité, la séc... | not-yet-due | |
| Trial is outside EEC | 2018-003430-33 | Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | bad-data | |
| Completed, report not yet due | 2018-003682-34 | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients | 2024-04-08 | not-yet-due |
| Reported results | 2019-000906-31 | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults with Syste... | 2020-09-15 | due-trials |
| Trial is outside EEC, and reported results | 2019-003921-99 | An open-label, single-arm, non-randomized phase 3 study to evaluate clinical efficacy, safety, and pharmacokinetics of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2020-000570-25 | A multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treat... | 2022-06-07 | bad-data |
| Exempt | 2020-000739-28 | A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to a... | not-yet-due | |
| Other | 2020-003918-12 | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-003162-12 | A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis | 2024-01-02 | bad-data |
| Trial is outside EEC | 2022-002333-34 | A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Chinese Subje... | bad-data |